interleukin-2 + xenogenic polyantigenic vaccine

A combination immunotherapy consisting of recombinant interleukin-2 (IL-2) and a xenogenic polyantigenic vaccine (XPV). The XPV is typically prepared from disrupted murine tumor cells (such as B16 melanoma and LLC carcinoma), providing a broad array of non-human tumor-associated antigens. This combination is designed to stimulate both cellular and humoral immune responses against cancer by leveraging the strong immunogenicity of xenogeneic antigens to break tolerance to self-tumor antigens. Interleukin-2 acts as an immune system modulator, promoting T-cell proliferation and activation, while the XPV serves as a source of diverse tumor-associated antigens that can trigger robust anti-tumor immunity. Clinical studies in advanced colorectal cancer have shown that this regimen increases cell-mediated reactivity to tumor antigens, elevates cytokine levels such as interferon-gamma and interleukin-4, induces antibody responses, and may prolong survival compared with controls[1][7]. The approach has also been explored in other solid tumors.

Other names

interleukin-2 and xenogenic polyantigenic vaccineinterleukin2 and xenogenic polyantigenic vaccineinterleukin 2 and xenogenic polyantigenic vaccineIL-2 + XPVIL-2 plus xenovaccineIL2 plus xenovaccineIL 2 plus xenovaccine